TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Titrated Oral Compared With Vaginal Misoprostol for Labor Induction at Term

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 34 to 42 weeks of gestation~* live singleton~* Bishop score \< or = 6~* reassuring fetal heart beat pattern~Exclusion Criteria:~* nonreassuring fetal heart beat pattern~* parity ovr five~* any contraindication to labor and/or vaginal delivery~* uterine scar~* suspected placental abruption with abnormal FHR pattern~* vaginal bleeding other than bloody show~* cervical dilatation of \> or = 4 cm~* uterine contractions \> or = 3 in 10 minutes~* significant maternal cardiac, renal or hepatic disease~* hypersensitivity to misoprostol or prostaglandin analogs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Titrated oral misoprostol
- 2 (Type: ACTIVE_COMPARATOR): Vaginal misoprostol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Bronchodilator Response of a Single Dose of Atrovent or Berotec on Top of Pharmacodynamic Steady State of Spiriva

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* diagnosis of COPD~* FEV1 \< 60% of predicted~* FEV1 \< 70% of FVC~* smoking history of 10 pack-years~Exclusion:~* significant other disease than COPD~* history of asthma, allergic rhinitis or blood eosinophil count \> 600mm3~* cardiac arrhythmia requiring drug therapy~* symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma~* recent history of MI (within past year)~* history of cancer within past 5 years~* life-threatening pulmonary obstruction~* cystic fibrosis or bronchiectasis; tuberculosis~* pulmonary resection

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol (Vitamin D3) Therapy in Chronic Kidney Disease (CKD) Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-85~* CKD stage 3-4 (GFR 15-59 ml/min/1.73 m2 body surface area, calculated by using the MDRD Study equation GFR Calculator)~* serum 25(OH)D concentrations ≤ 30 ng/mL, and serum PTH levels \>70 pg/mL documented within the last six months~Exclusion Criteria:~* History of liver failure (serum AST or ALT \> 3-fold the upper limit of normal)~* requiring dialysis at any stage of the study~* history of intestinal malabsorption or chronic diarrhea~* serum calcium level (corrected for serum albumin) \> 10.5 mg/dL~* calcium x phosphorus product \>70~* treatment with more than 1000 IU of vitamin D per day, or current treatment with a vitamin D analogue or calcimimetic~* an anti-epileptic medication and other medications which can affect vitamin D metabolism (e.g., phenobarbital, phenytoin, rifampicin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- Cholecalciferol (Type: ACTIVE_COMPARATOR): D3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 75 years old~* Females must be of non-childbearing potential; If of child-bearing potential, must have negative pregnancy test and confirm the use of one of the appropriate means of contraception.~* Males must agree to use an appropriate method of barrier contraception or have documented surgical sterilization~* Subject meets definition of IBS-C using Rome III Criteria for the Diagnosis of IBS~* A colonoscopy based on AGA guidelines; every 10 years at ≥ 50 years old, or the occurrence of any warning signs~Exclusion Criteria:~* Functional diarrhea as defined by Rome III criteria~* IBS with diarrhea (IBS-D), mixed IBS (IBS-M), or unsubtyped IBS as defined by Rome III criteria~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening; including but not limited to cancer, inflammatory bowel disease, diverticulitis, duodenal ulcer, erosive esophagitis, gastric ulcer, pancreatitis (within 12 months of screening), cholelithiasis, amyloidosis, ileus, non-controlled GERD, gastrointestinal obstruction, ischemic colitis or carcinoid syndrome.~* Subject has a history or current evidence of laxative abuse (in the clinical judgment of the physician)~* Hepatic dysfunction (ALT \[SGPT\] or AST \[SGOT\] \>2.5 times the upper limit of normal) or renal impairment (serum creatinine \> 2mg/dL)~* Any evidence of or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year~* Any surgery on the stomach, small intestine or colon, excluding appendectomy or cholecystectomy (unless within 60 days of screening visit)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 50mg BID (Type: EXPERIMENTAL): Tenapanor
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Delivery of Vitamin D3 as Vitamin D Supplementation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~all men and women with vitamin D insufficiency and deficiency Must be able to apple the topical vitamin D3 Must be willing to sign and informed consent~Exclusion Criteria:~* Those who have normal 25OHD levels

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Topical Vitamin D3 application (Type: EXPERIMENTAL): Intervention is Application of topical Vitamin D3 Frequency: Daily Dosage: 1 gram (5000 IU) Duration: 120 days
- Aloe vera gel Application (Type: ACTIVE_COMPARATOR): Application of Aloe vera gel will be carried out Dosage: 1 gram Frequency: Daily Duration: 120 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male/Female patients aged 18 years or over~* Patients must provide written informed consent~* Part I: Patients with histologically confirmed, locally advanced or metastatic solid tumors. Part II and Part III: Patients with histologically confirmed, pancreatic adenocarcinoma for which the established therapy is Abraxane®/Gemcitabine (clinical standard of care)~* Life expectancy above 3 months~* Patients willing to comply with treatment follow-up~* ECOG Performance status 0 or 1~* Adequate baseline organ function (hematologic, liver, renal and nutritional)~* Use a reliable method of contraception in fertile men and women~Exclusion Criteria:~* Active infection or other serious illness or autoimmune disease~* Treatment with live attenuated vaccines in the last three weeks~* Known chronic liver disease (liver cirrhosis, chronic hepatitis)~* Treatment with another investigational agent within its five half-lives prior to VCN-01 infusion~* Viral syndrome diagnosed during the two weeks before inclusion~* Chronic immunosuppressive therapy~* Concurrent malignant hematologic or solid disease~* Pregnancy or lactation. Patients must agree to use effective contraception or be surgically sterile.~* Patients receiving full-dose anticoagulant / antiplatelet therapy~* Adequate levels of neutralizing antibodies against adenovirus~* Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein pathway germinal deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part I: Dose Escalation, Single Agent (Type: EXPERIMENTAL): Single intravenous injection of VCN-01 oncolytic adenovirus
- Part II: Dose Escalation, Combination (Type: EXPERIMENTAL): Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine
- Part III: Dose Escalation, Combination, delayed schedule (Type: EXPERIMENTAL): Single intravenous injection of VCN-01 oncolytic adenovirus in combination with Abraxane®/Gemcitabine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Enterovirus 71（EV71） Inactivated Vaccine in Children Aged 36-71 Months

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers ≥ 2 years old;~* Proven legal identity;~* Participants or guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrolment.~Exclusion Criteria:~* Prior vaccination with EV71 vaccine;~* History of hand, foot and mouth disease;~* History of allergy to any vaccine or vaccine ingredient, asthma, serious adverse reactions to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc;~* Congenital malformation, developmental disorders, genetic defects, or severe malnutrition;~* Autoimmune disease or immunodeficiency/immunosuppressive;~* Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness;~* History of thyroidectomy, no spleen and functional spleen;~* Diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders;~* Receipt of any of the following products:~  1. Any immunosuppressant, cytotoxic medicine, or inhaled corticosteroids (except corticosteroid spray for treatment of allergic rhinitis or corticosteroid treatment on surface for acute non-complicated dermatitis) within 6 month prior to study entry~ 2. Blood products within 2 months prior to study entry~ 3. Any other investigational products (drug or vaccine）within 30 days prior to study entry~ 4. Any live attenuated vaccine within 14 days prior to study entry~ 5. Any subunit vaccine or inactivated vaccine within 7 days prior to study entry;~* Acute disease or acute stage of chronic disease within 7 days prior to study entry;~* Axillary temperature \> 37.0 °C;~* Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 71 Months
- Healthy Volunteers: t

Study Arms:
- Experimental group (Type: EXPERIMENTAL): 36-71 months old children-experimental EV71 vaccine.
- Vaccine-controlled group (Type: ACTIVE_COMPARATOR): 36-71 months old children-control EV71 vaccine.
- Age-controlled group (Type: ACTIVE_COMPARATOR): 6-35 months old children-experimental EV71 vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients (\>=18 years)~2. Females must be either post-menopausal for one year, surgically sterile or using effective contraceptive methods (e.g. intra-uterine device, hormonal contraceptives).~3. Patients with moderate essential hypertension (WHO):~Exclusion Criteria:~1. Severe hypertension (WHO)~2. Pregnant or nursing women~3. Treated hypertensive patients with controlled hypertension under current therapy (MSDBP \< 90 mmHg and MSSBP \< 140 mmHg)~4. A history of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, and heart failure NYHA II - IV

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 to 90 years of age inclusive~* Female patients can participate if they are surgically sterile or completed menopause or females capable of having children and agree not to attempt pregnancy while receiving IV study therapy and for a period of 7 days after~* Has pyuria with \>/= 10 WBCs (white blood cell) and has a positive urine culture within 48 hours of enrollment containing \>/=10 to the fifth CFU (colony forming unit ) /ml of a recognized uropathogen known to be susceptible to IV study therapy (CAZ-AVI and doripenem)~* Demonstrates either acute pyelonephritis or complicated lower UTI without pyelonephritis.~Exclusion Criteria:~* Urine pathogen is a Gram-positive pathogen or a uropathogen resistant to CAZ-AVI or doripenem~* Patient's urine culture at study entry isolates more than 2 microorganisms regardless of colony count or patient has a confirmed fungal UTI~* Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant~* Patient is immunocompromised~* Patient is considered unlikely to survive the 6- to 8-week study period or has a rapidly progressive or terminal illness including septic shock which is associated with a high risk of mortality

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ceftazidime - Avibactam ( CAZ-AVI) (Type: EXPERIMENTAL): IV treatment
- Doripenem (Type: ACTIVE_COMPARATOR): IV treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Active rheumatoid arthritis~* Inadequate response to stably dosed methotrexate~Exclusion Criteria:~* Current therapy with any DMARD or biologic other than methotrexate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CP 690,550 1 mg BID (Type: EXPERIMENTAL): None
- CP 690,550 10 mg BID (Type: EXPERIMENTAL): None
- CP 690,550 15 mg (Type: EXPERIMENTAL): None
- CP 690,550 3 mg BID (Type: EXPERIMENTAL): None
- CP 690,550 5 mg BID (Type: EXPERIMENTAL): None
- CP-690,550 20 mg QD (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): Dummy tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female over 18 yrs.~* Female subjects of childbearing potential must have negative pregnancy test and provide contraception.~* Subjects must have confirmed diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes.~* Subjects who are or have been insufficiently responsive to IOP reducing monotherapy and use of either study medication is deemed appropriate.~* Subjects able to complete questionnaires and provide informed consent.~Exclusion Criteria:~* Female subjects who are pregnant, planning to become pregnant during study period, breast feeding or not practicing a reliable method of birth control.~* Subjects wherein the study drugs are containdicated.~* Subjects who have had introcular surgery with 6 months (3 months for laser).~* Subjects with known side effects/ allergy or sensitivity to any component of study treatments.~* Subjects with any uncontrolled systemic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): brimonidine/timolol. Fixed-combination monotherapy.
- 2 (Type: ACTIVE_COMPARATOR): dorzolamide/timolol. Fixed-combination monotherapy.
- 3 (Type: ACTIVE_COMPARATOR): prostaglandin analogue+ brimonidine/timolol fixed combination.
- 4 (Type: ACTIVE_COMPARATOR): prostaglandin analogue+dorzolamide/timolol fixed combination.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)~* Subjects must be initiating first-line carboplatin/paclitaxel chemotherapy within 8 days after randomization and expected to receive at least 4 cycles of chemotherapy~* Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1~Exclusion Criteria:~* Small cell lung cancer (SCLC) or mixed SCLC and NSCLC~* Central nervous system (CNS) metastases~* Malignancy other than NSCLC~* Palliative radiotherapy for bone lesions inside the thorax~* Prior radiotherapy of bone marrow~* Known to be positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)~* Life expectancy \< 6 months~* Woman of child-bearing potential who is pregnant or is breast feeding or who is not consenting to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment~* Man with a partner of childbearing potential who does not consent to use highly effective methods of birth control during treatment and for an additional 6 months after the last administration of the protocol specified treatment~* Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products~* Other inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- ABP 215 (Type: EXPERIMENTAL): Participants received 15 mg/kg ABP 215 administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.
- Bevacizumab (Type: ACTIVE_COMPARATOR): Participants received bevacizumab 15 mg/kg administered as an intravenous (IV) infusion every 3 weeks (Q3W) for 6 cycles and carboplatin and paclitaxel chemotherapy Q3W for at least 4 and not more than 6 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete